RSS

IPIX Innovation Pharmaceuticals Inc

Last Post: 10/20/26
Followers: 278
Posts Today: 0
Views Today: 9165

IPIX Stock Quote & Tools

$0.0006 ▲ +0.0001 (+20.00%) As of Oct 23, 1:15 PM EDT
Last0.0006
$ Chg0.0001
Open0.0006
High0.0006
Beta140.0971
Year High0.050
Market Cap311.0K
P/B Ratio0.09
EPS-0.01
Avg Vol (30d)159.3K
Volume1.08M
% Chg+20.00%
Prev Close0.0005
Low0.0005
VWAP0.00051
Year Low0.000
Total Shares518.35M
Shares Out514.01M
Float391.87M
ExchangeOTCID
Healthcare Biotechnology & Life Sciences

IPIX Stock Message Board Discussion

  1. incubus

Top 10 Most Recent News Articles

CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 181

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 98

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 339

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 163

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading

Top 5 Most Recently Viewed Articles

Stocks Rebound in Volatile Trading After Major Sell-off

Updated Category Markets Views 525

Global Stocks See Slight Uptick Amid Market Volatility Tuesday saw global stocks climb, yet trading was erratic. Following Monday's forceful selloff, investors remained wary. Officials of central banks aimed at reassuring the markets. Some respite came from Tokyo overnight's 10% rebound in Nikkei. Investor mood was still wary, though. U.S. stock futures displayed mixed...

Continue Reading
Projecting the Growth of the Femtech Market Through 2031

Updated Category News Views 77

The Femtech market stood at an impressive USD 33.92 billion back in 2023, setting the stage for its remarkable leap to a projected value of USD 113.53 billion by 2031. That’s a compound annual growth rate (CAGR) of about 16.3%. So, what's fueling this explosion? For starters, it's all about the rising awareness surrounding women's health issues—a topic that finally...

Continue Reading
Vestis Corporation Class Action Lawsuit: Key Details to Know

Updated Category News Views 494

Class Action Lawsuit Against Vestis Corporation Pomerantz LLP is drawing attention to a class action lawsuit filed against Vestis Corporation (NYSE: VSTS) concerning allegations of securities fraud. Investors who have incurred losses due to their investment in Vestis are encouraged to take action. Deadline for Investors Investors have until August 8, 2025, to request the...

Continue Reading
Associated Banc-Corp Sets Public Offering for Growth Funding

Updated Category News Views 215

Associated Banc-Corp Announces Stock Offering Associated Banc-Corp (NYSE: ASB) has recently made headlines with its announcement regarding a public offering of its common stock. The company is set to offer 12 million shares, each with a par value of $0.01, at a price of $25.00 per share. This means the total gross proceeds from this offering are expected to reach an...

Continue Reading
Olaplex Holdings Inc. to Engage at Canaccord Genuity Growth Conference

Updated Category News Views 138

Olaplex Holdings Inc. to Engage at Canaccord Genuity Growth Conference Olaplex Holdings, Inc. (NASDAQ: OLPX) has recently confirmed its engagement in the Canaccord Genuity 45th Annual Growth Conference. This prestigious event is set to take place soon, where the company will have a platform to showcase its commitment to innovation in the beauty and hair care industry....

Continue Reading